Anti-metalloprotease antibody for diagnosis and treatment of cancers
US11160873B2 · kind B2 · utility
0Cited by
3References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 5, 2018 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Aug 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.